A CDC advisory panel voted to recommend RSV vaccines for at-risk adults 50 to 59, a sought-after expansion by vaccine makers ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult ...

Due to a law enacted in 2023, Medicare now covers the RSV vaccine for older adults under Part D, which typically covers prescription drugs. This means you shouldn’t incur any out-of-pocket costs.

the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease. According to the CDC, between 15,000 - 20,000 ...

All three vaccines are approved for use in the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ages ≥60 years. In addition, Arexvy is approved for prevention of LRTD ...